Vancomycin Hydrochloride
Sponsors
Tartu University Hospital, Vedanta Biosciences Inc., Fakultni Nemocnice Bulovka, Universidade Federal do Ceara, University of British Columbia
Conditions
Clostridioides difficile infectionDeep Brain StimulationDental CariesImplantable Neural StimulatorMild-to-moderate ulcerative colitisOpen tíbia FractureOsteomyelitis TibiaPeriprosthetic Joint Infection
Phase 2
Intrawound Vancomycin Prophylaxis for Neural Stimulator
NCT03221023
Start: 2017-09-15End: 2021-12-15Target: 900Updated: 2020-10-30
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis
CompletedCTIS2024-512558-40-00
Start: 2023-05-11End: 2025-08-11Target: 74Updated: 2025-07-28
ANtibiotic TReatment OPtimisation – randomised controlled trial of Clostridioides difficile infection therapy (ANTROP-I)
RecruitingCTIS2024-518607-21-00
Start: 2025-09-25Target: 244Updated: 2025-10-27
Phase 3
Phase 4
Topical Vancomycin Over Sternal Edge in Cardiac Surgery
CompletedNCT04500275
Start: 2020-07-01End: 2025-03-31Updated: 2025-04-08
Vancomycin treatment in critically ill adults using model-informed precision dosing tool – prospective low-intervention clinical trial. (ProVanc)
Active, not recruitingCTIS2023-509003-32-00
Start: 2024-03-01Target: 56Updated: 2024-12-02